Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LD Micro Invitational XIV 2024
Log in at this address to view Chris Bunka's presentation yesterday.
https://ldinv14.sequireevents.com/
Shares. Someone's getting them, while the getting's good!
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
Kelowna, British Columbia – April 30, 2024 – TheNewswire –Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain existing warrants to purchase an aggregate 2,917,032 shares of its common stock, as to 1,618,330 warrants exercised at an exercise price of $0.97 per share, and 1,298,702 warrants exercised at $2.185 per share, originally issued in October 2023 and February 2024, respectively.
With this exercise, there are zero remaining warrants exercisable at $0.97 and 259,741 warrants unexercised at $2.185. The gross proceeds to the Company from the exercise are expected to be approximately $4.7 million, prior to deducting estimated offering expenses.
In consideration for the early exercise of the existing warrants for cash, and the payment of $0.125 per each new warrant, aggregating $364,629 in proceeds to the Company, Lexaria is issuing 2,917,032 new warrants, each new warrant entitling the holder to purchase one (1) new share of common stock. The new warrants are immediately exercisable at an exercise price of $4.75 per share, and will expire on February 16, 2029 if not exercised before that date.
The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes.
“These additional cash proceeds of $4.7 million further extend Lexaria’s operational runway deep into 2025 and allow us to execute our 2024 plans at an aggressive pace,” said Chris Bunka, CEO of Lexaria. “The exercise price of the replacement warrants, at $4.75, is a significant premium to current market prices and, in our opinion, a sign of confidence in Lexaria’s future.”
The new warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the shares of Class A common stock issuable upon exercise of the new warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the new warrants issued in the private placement and the shares of common stock underlying the new warrants may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issuable upon the exercise of the new warrants.
In connection with the issuance of the new warrants, Lexaria is required to provide H.C. Wainwright with its tail consideration of 6% of the cash proceeds received for the warrant exercises and issuance of the new warrants and to issue 102,097 warrants with an exercise price of $5.9375 per share and having the same terms and conditions as the new warrants.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 41 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
Eli Lilley share price is soaring as their GLP-1 drug flies off the shelves! Just imagine if it could be orally administered with DHT!
Wow! You look away for a few minutes and the stock jumps over 20%.
I think he's mistaken about the hypertension trial being underway, they have FDA approval but I don't believe it's started.
https://letstoke.us19.list-manage.com/track/click?u=f2e0706764f99154e3a11feb5&id=cdea306711&e=9cbb5a4bc7
Lexaria Bioscience (NASDAQ: LEXX): dipped to $2.12 last week which is a market cap of $27 million.
On March 12, 2024, as LEXX was rallying strongly, I said I didn’t think LEXX’s market cap would fall
below $30 million and last week it did. Remember, LEXX has a hypertension solution approved by the
FDA for additional testing that is underway with early results expected shortly. It also has a diabetes/obesity that is probably a year from gaining FDA testing approval. There should be several results
oriented news releases this year. These are two potentially major projects, either one of which can
justify a $30 million market cap. As LEXX falls back, it gives investors a second chance to grab the ring.
If I believed LEXX was attractive at $3, I like it even more at around $2. I conclude that LEXX has the
potential to rally back strongly.
Lexaria’s Shakespearian Correction – Much Ado About Nothing
https://www.letstoke.biz/_files/ugd/449582_f3c7ffb8161b40a1a2cd3dc4651cd1df.pdf
I call it an amazing gift from the short sellers to anyone wishing to get in for the first time or add to their positions!
Special Report: Lexaria has a week for the record books
https://www.letstoke.biz/_files/ugd/449582_b11b869ac5744f18a682429ffbf12660.pdf
https://www.msn.com/en-ca/health/other/obesity-drug-wegovy-is-approved-to-cut-heart-attack-and-stroke-risk-in-overweight-patients/ar-BB1jzFG3?ocid=msedgntp&pc=DCTS&cvid=2c4aee8abeb143b1929c74cb4214ea55&ei=210
The FDA cautioned that Wegovy carries the risk of serious side effects, including thyroid tumors and certain cancers. Other possible side effects can include low blood sugar; pancreas, gallbladder, kidney or eye problems; and suicidal behavior or thinking.
About a third of the more than 17,600 participants in the clinical trial reported serious side effects. About 17% in the group that took Wegovy and about 8% of those who received placebo left the study because of those effects.
At least the taste is masked. LOL
Hello 5 bucks, my old friend!
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
2024-03-07 09:10 ET - News Release
First-ever dissolvable DehydraTECH-GLP-1 oral dose formulation to be tested
Rybelsus® semaglutide will act as the positive control
KELOWNA, BC / ACCESSWIRE / March 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has hired a contract research organization ("CRO") to perform the Company's second DehydraTECH-powered glucagon-like peptide 1 ("GLP-1") human pilot study #2 (the "Study").
The Study will be a randomized, crossover, placebo-controlled investigation that will compare three dose formulations each at a 7 mg semaglutide dose:
a positive control Rybelsus® swallowed tablet;
DehydraTECH-semaglutide swallowed capsules; and,
for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet.
Semaglutide swallowed into the stomach/intestine absorbs into the bloodstream at an exceptionally low rate typically at less than 1%, when it does not use any absorption technology because, in part, the acidic environment of the stomach is known to seriously degrade GLP-1 drugs.
"DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the buccal/sublingual tissues of the mouth and throat," said Chris Bunka, CEO of Lexaria Bioscience Corp. "If this new Study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets, could be within reach."
Manufacturing of the test articles for this Study is anticipated to be completed within 30 days. Independent Review Board approval is required before the Study can commence, and the Company will provide our next update when dosing has begun.
CORRECTION
In Lexaria's press release of March 4, we described an upcoming animal study as having an 8-week duration. That was a typographical error: the correct animal study duration is 12-weeks.
About the Study
Many design characteristics of the Study will be fundamentally the same as in Lexaria's initial human pilot study. The DehydraTECH-semaglutide test articles will be compound formulated using crushed Rybelsus®tablets strictly for research purposes. The Study is designed to measure tolerability and side effects, blood levels of semaglutide, and blood glucose levels. Blood samples will be taken multiple times during the first 10 hours post dosing; a final blood draw will be taken 24 hours after dosing; and, a standardized meal will be fed to the test subjects at a point in time after dosing. Eight healthy subjects are expected to be dosed with each test article following a cross over study design across three study visits.
About Semaglutide
Rybelsus® (semaglutide) is the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic® and Wegovy®, administered by injection, to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk®.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Isn't it great, I see $4.84 in after-hours trading. We've blown through a two-year high on sustained, high volume.
It looks like their eye drops are made with THC, not CBD. An impressive move nonetheless, considering there are other drops available that effectively reduce iintraocular pressure.
It looks like their eye drops are made with THC, not CBD. An impressive move nonetheless, considering there are other drops available that effectively reduce iintraocular pressure.
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
(via TheNewswire)
Lexaria Bioscience Corp.
Multiple DehydraTECH-GLP-1 and DehydraTECH-CBD formulations to be tested
Chronic dosing over a 12-week treatment period
Will assess weight loss and blood glucose level control
Efficacy through possible brain absorption delivery enhancement to be assessed
Kelowna, British Columbia / TheNewswire / March 5, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces details of an 8-week animal study WEIGHT-A24-1 (the “Study”) to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination.
The contract for the Study has been awarded to a third-party, Health Canada-licensed Canadian research laboratory. Manufacturing of the compositions for the first 8 of the 12 arms of the Study has already been completed, and those arms will commence as soon as the testing laboratory is able to do so, expected to begin within 45 days.
Detailed information of the 12 Study arms is as noted:
Group 1: DehydraTECH-CBD (composition “A”)
Group 2: DehydraTECH-CBD (composition “B”)
Group 3: DehydraTECH-CBD (composition “C”)
Group 4: DehydraTECH-CBD (composition “D”)
Group 5: DehydraTECH-GLP-1 (re-formulated Rybelsus “E”)
Group 6: DehydraTECH-GLP-1 (re-formulated Rybelsus “F”)
Group 7: DehydraTECH-GLP-1 (pure semaglutide “G”)
Group 8: DehydraTECHGLP-1 (pure liraglutide “H”)
Group 9: Combination of one of E, F, or G and one of A, B, C, or D (TBD)
Group 10: Combination of H and one of A, B, C, or D (TBD)
Group 11: Vehicle (placebo) arm
Group 12: Positive control arm
Each arm of the Study will be dosed for an 8-week period following an acclimation period. During the Study, over 1,500 blood plasma samples will be collected from the total rat population of 72 animals for purposes of detailed pharmacokinetic drug delivery analyses. Body weight and blood glucose readings will be taken prior to Study start and at regular intervals during and at conclusion of the dosing period. Upon completion of the Study, brain tissue will be analysed to help determine whether DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms, as Lexaria has evidenced numerous times in previous similar animal studies. LC-MS/MS and other techniques will be used to analyse samples. Also, the Study will allow examination of DehydraTECH-processed semaglutide with and without the salcaprozate sodium "SNAC" technology currently found within Rybelsus® tablets. We will be collecting and reporting interim results prior to the end of the Study.
Study arms 9 and 10 will have a later start-date due to some information outputs required from the other Study arms before they and study arms 11 and 12 can commence. The Company will provide an update when animal dosing has begun.
In previous animal research with two other molecules, including cannabidiol, Lexaria demonstrated through brain tissue examination that DehydraTECH processing can enable higher levels of drug delivery across the blood-brain-barrier and directly into brain tissue. It is unknown, today, whether DehydraTECH processing can deliver higher quantities of GLP-1 drugs into brain tissue, and Study WEIGHT-A24-1 is designed to answer that question in animals.
Recent research has indicated “that a small peptide GLP-1R agonist penetrates the brain and activates a subset of GLP-1R–expressing neurons in the arcuate nucleus to produce weight loss.” Lexaria believes that, if it can evidence that DehydraTECH processing of GLP-1 drugs can enable greater penetration into brain tissue, then this may help to explain how the GLP-1 drug(s) powered by DehydraTECH may be more effective at enhancing beneficial outcomes such as weight loss and blood sugar control. In turn, this could also potentially allow for lower dosing and a concomitant reduction in adverse side effects.
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 39 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company’s ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
Copyright (c) 2024 TheNewswire - All rights reserved.
T Ltd. All rights reserved.
Someone just crossed? 225,054 shares.
Special Report: Where does Lexaria go from here? HIGHER!.
https://www.letstoke.biz/_files/ugd/449582_8ca51684c9ba4f8983e81d95e513d932.pdf
Lots like a 'Sell-on-news event' down .75 on pre-market.
Ted Ohashi, in response to comments about a possible 'sell-on-news event'.
"Just so you know. I am just concluding some research that indicates the LEXX rally may be less to do with the IND application and more to do with the GLP-1 potential for diabetes/obesity. This sector is white hot in the states. You know from what I've been saying in the Let's Toke Business newsletter that the IND application is very important to me and I have also been thinking about a "sell on history" response but it looks like there are a couple of drivers and from a US market point of view, the GLP-1 might be even more important. I'm just looking at a few more items to solidify my conclusion. In other words there may not be a "sell on history" correction."
Or ran into it. LOL
Wow! Just smashed through the 3 dollar level!